One of the most exciting and successful historical demonstrations of translational immunotherapy is the development of monoclonal antibodies, says Robert L. Ferris, MD.
Robert L. Ferris, MD
One of the most exciting and successful historical demonstrations of translational immunotherapy is the development of monoclonal antibodies. Since the early 1900s when Paul Ehrlich, MD, envisioned these agents as “magic bullets,” monoclonal antibodies have been studied, coming into their own because of investigators’ ability to isolate and produce them in large-scale batches for research and clinical applications.
Large-scale batches for research and clinical applications. In 1984, Niels K. Jerne, MD; Georges J.F. Köhler, PhD; and César Milstein, PhD, who had discovered the principle for production of monoclonal antibodies, were awarded the 1984 Nobel Prize in Physiology or Medicine. Monoclonal antibodies demonstrated their potency and exquisite specificity for a particular target. An example is the linkage of chemotherapy as a payload onto the anti–HER2-specific antibody trastuzumab (Herceptin). In 2013, the FDA approved trastuzumab emtansine (T-DM1; Kadcyla) for HER2-expressing breast cancers resistant to trastuzumab or taxane chemotherapy.
Subsequently, the discovery that monoclonal antibodies could block inhibitory immune checkpoint receptors, such as PD-1 and CTLA-4, led to the 2018 Nobel Prize in Physiology or Medicine being awarded to James P. Allison, PhD, and Tasuku Honjo, MD, PhD.
The most recent development involves the field of theranostics, which uses radiolabeled monoclonal antibodies to target a particular tumor selective protein. In this issue of Targeted Therapies in Oncology, we review a series of theranostic strategies for not only diagnostic imaging of disseminated disease using radiolabeled monoclonal antibodies, but also for modifying the dosage and radioisotope to deliver therapeutic antitumor doses of the radiation in a highly targeted fashion, even for systemically metastatic cancer (see pages 30-34). There are now several theranostic antibodies that target cancer, the most recent being prostatespecific membrane antigen for prostate cancer.
The next generation of monoclonal antibodies can increase their targets in a single molecule, which are bispecific and trispecific, harnessing multiple specificities. These multimeric antibodies effectively increase the local concentration of antibody in the tumor microenvironment and harness the biology of multiple pathways that can be targeted for inhibition or stimulation, leading to more effective cancer therapy. These are truly amazing times that couple deep knowledge of biology with protein engineering, embodying the “magic bullets” envisioned more than 100 years ago.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer
July 23rd 2024In separate, live virtual events, Michael J. Birrer, MD, PhD, and Jubilee Brown, MD, surveyed participants on the treatment of a postmenopausal woman with stage IVA endometrial cancer after first-line chemotherapy.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More